Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Guidelines for the treatment of ulcerative colitis in remission

Guidelines for the treatment of ulcerative colitis in remission The role is reviewed of sulphasalazine, 5‐aminosalicylic acid (5‐ASA), immunosup‐pressive agents and corticosteroids in the maintenance treatment of ulcerative colitis in remission. Sulphasalazine and oral 5‐ASA are the drugs of first choice in preventing relapses for patients suffering from intermittent chronic ulcerative colitis. Rectally administered 5‐ASA may be a valid alternative for treating patients with proctitis and left‐sided ulcerative colitis. The optimal dosage of oral 5‐ASA in the maintenance therapy of ulcerative colitis in remission is not clear. However, there is evidence that a higher dose of 5‐ASA is more effective than low dosage in preventing relapses in patients in remission. For patients with chronically active or steroid‐dependent ulcerative colitis who have achieved remission while taking immunosup‐pressants, continuing azathioprine or 6‐mercaptopurine is indicated. Existing data cast doubts as to whether or not continuous maintenance is still necessary in patients suffering from intermittent chronic ulcerative colitis with prolonged endoscopic, clinical and histological remission. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Gastroenterology & Hepatology Wolters Kluwer Health

Guidelines for the treatment of ulcerative colitis in remission

Loading next page...
 
/lp/wolters_kluwer/guidelines-for-the-treatment-of-ulcerative-colitis-in-remission-A3me7COELC
Copyright
© Rapid Science Publishers ISSN 0954‐691X
ISSN
0954-691X
eISSN
1473-5687

Abstract

The role is reviewed of sulphasalazine, 5‐aminosalicylic acid (5‐ASA), immunosup‐pressive agents and corticosteroids in the maintenance treatment of ulcerative colitis in remission. Sulphasalazine and oral 5‐ASA are the drugs of first choice in preventing relapses for patients suffering from intermittent chronic ulcerative colitis. Rectally administered 5‐ASA may be a valid alternative for treating patients with proctitis and left‐sided ulcerative colitis. The optimal dosage of oral 5‐ASA in the maintenance therapy of ulcerative colitis in remission is not clear. However, there is evidence that a higher dose of 5‐ASA is more effective than low dosage in preventing relapses in patients in remission. For patients with chronically active or steroid‐dependent ulcerative colitis who have achieved remission while taking immunosup‐pressants, continuing azathioprine or 6‐mercaptopurine is indicated. Existing data cast doubts as to whether or not continuous maintenance is still necessary in patients suffering from intermittent chronic ulcerative colitis with prolonged endoscopic, clinical and histological remission.

Journal

European Journal of Gastroenterology & HepatologyWolters Kluwer Health

Published: Sep 1, 1997

There are no references for this article.